Want to see AU:ARX full AI Analyst Report?
ARX Stock Chart & Stats
AU$0.56
AU$0.02(3.57%)
At close: 4:00 PM EDT
AU$0.56
AU$0.02(3.57%)
Day’s Range― - ―
52-Week RangeAU$0.50 - AU$0.80
Previous CloseN/A
Volume338.11K
Average Volume (3M)302.12K
Market Cap
AU$209.27M
Enterprise ValueAU$196.49
Total Cash (Recent Filing)AU$22.60M
Total Debt (Recent Filing)AU$5.31M
Price to Earnings (P/E)32.1
Beta0.54
Next Earnings
Nov 26, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding345,902,650
10 Day Avg. Volume330,836
30 Day Avg. Volume302,123
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)2.48
Price to Sales (P/S)2.23
P/FCF Ratio24.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.94Price Target Upside67.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$120.56M
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue GrowthSustained top-line growth over multiple years reflects expanding clinical adoption and distribution reach. This scale improves operating leverage potential, funds R&D and commercialization, and provides a durable base to convert market penetration into predictable revenue streams over the medium term.
High Gross Margins And Profitability InflectionVery high gross margins indicate a favorable product cost structure and pricing power in ECM-based surgical products. The recent shift to operating and net profitability suggests the business model can absorb SG&A and scale to sustainable earnings if revenue growth continues.
Conservative Balance Sheet And Positive Cash FlowA marked improvement to positive operating and free cash flow combined with low leverage gives the company financing flexibility. Conservative debt levels and positive cash conversion reduce refinancing risk and support reinvestment in sales and product development over the next several quarters.
Bears Say
Historic Earnings/Cash Flow VolatilityPrior multi-year losses and negative cash flow mean recent profitability may be cyclically sensitive. The business has not yet demonstrated durability across downturns; investors should expect execution and cash conversion risks until multiple quarters of positive flows are sustained.
Modest Net Margin Despite High Gross MarginA large gap between gross and net margin signals elevated operating or commercial expenses. Until operating leverage is consistently realized, profitability remains thin, limiting internal capital available for R&D, sales expansion, or buffering against reimbursement and pricing pressures.
Revenue Dependence On Procedure Volumes & ChannelsRevenue is structurally tied to clinical adoption rates and distributor performance. This reliance can slow growth if procedure volumes fall or partners underperform, and it concentrates execution risk outside direct company control, complicating predictable scaling over months to quarters.
Aroa Biosurgery Ltd News
ARX FAQ
What was Aroa Biosurgery Ltd’s price range in the past 12 months?
Aroa Biosurgery Ltd lowest share price was AU$0.49 and its highest was AU$0.80 in the past 12 months.
What is Aroa Biosurgery Ltd’s market cap?
Aroa Biosurgery Ltd’s market cap is AU$209.27M.
When is Aroa Biosurgery Ltd’s upcoming earnings report date?
Aroa Biosurgery Ltd’s upcoming earnings report date is Nov 26, 2026 which is in 104 days.
How were Aroa Biosurgery Ltd’s earnings last quarter?
Aroa Biosurgery Ltd released its earnings results on May 25, 2026. The company reported AU$0.017 earnings per share for the quarter, beating the consensus estimate of AU$0.004 by AU$0.012.
Is Aroa Biosurgery Ltd overvalued?
According to Wall Street analysts Aroa Biosurgery Ltd’s price is currently Undervalued.
Does Aroa Biosurgery Ltd pay dividends?
Aroa Biosurgery Ltd does not currently pay dividends.
What is Aroa Biosurgery Ltd’s EPS estimate?
Aroa Biosurgery Ltd’s EPS estimate is 0.
How many shares outstanding does Aroa Biosurgery Ltd have?
Aroa Biosurgery Ltd has 345,902,650 shares outstanding.
What happened to Aroa Biosurgery Ltd’s price movement after its last earnings report?
Aroa Biosurgery Ltd reported an EPS of AU$0.017 in its last earnings report, beating expectations of AU$0.004. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aroa Biosurgery Ltd?
Currently, no hedge funds are holding shares in AU:ARX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aroa Biosurgery Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.94 (67.86% Upside)
AU$0.94 (67.86% Upside)
Blogger Sentiment
Bullish
AU:ARX Sentiment 100%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth AU$125.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.55%
Trailing 12-Months
Company Description
Aroa Biosurgery Ltd
Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories. Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds. Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications. Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.
ARX Stock 12 Month Forecast
Average Price Target
AU$0.94
▲(67.86% Upside)
Technical Analysis
Polynovo
―
Cochlear
―
Impedimed Limited
―
OncoSil Medical Ltd
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―







